How to Stop Menopause Hormone Therapy Safely: A Complete Clinical Guide

At a glance

• Fixed stop date / none; duration follows a documented indication with periodic reassessment [1]
• Current estrogen labels / still say lowest effective dose, shortest duration, periodic reevaluation [3]
• Hot flash duration / median 7.4 years total, 4.5 years after the final period, in SWAN [4]
• Nonhormonal, Level I support / CBT, clinical hypnosis, SSRI or SNRI, gabapentin, fezolinetant [2]
• Bone / hormone therapy has been shown to prevent bone loss and fracture [1]

Is there a time limit on hormone therapy?

The Menopause Society's 2022 position statement says risks differ by type, dose, duration, route, timing of initiation and whether a progestogen is used [1]. It supports longer durations when there is a documented indication, with periodic reevaluation of benefits and risks [1].

On 2025-11-10 the FDA asked for the boxed recommendation to use the lowest effective dose for the shortest time to be removed [5]. Current labels still carry that wording: the Premarin label (effective 2026-06-04) says estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks [3].

On February 12, 2026, FDA approved boxed-warning changes for six products [6]. As of October 29, 2026, the Premarin and Prempro labels still carried the older boxed warning [3][7].

What the labels say about stopping

The Premarin dosing section says to start at 0.3 mg daily for moderate to severe vasomotor symptoms, adjust by response, and re-evaluate postmenopausal women periodically to determine whether treatment is still necessary [3].

The label says to discontinue estrogen immediately if a stroke or venous thromboembolism occurs or is suspected [3].

If hot flashes return

In SWAN, a study of 3,302 women at 7 US sites, the median total duration of frequent hot flashes or night sweats was 7.4 years, and the median persistence after the final menstrual period was 4.5 years [4].

The Menopause Society's 2023 nonhormone statement gives Level I support to cognitive behavioral therapy, clinical hypnosis, SSRIs or SNRIs, gabapentin and fezolinetant. It does not recommend paced respiration (Level I) or supplements and herbal remedies (Levels I to II) [2].

Fezolinetant (Veozah) is a neurokinin 3 receptor antagonist taken as 45 mg once daily [8]. Its label carries a boxed warning for serious liver injury and requires liver tests before starting and monthly for the first three months, then at 6 and 9 months [8].

Frequently asked questions

›How long can hormone therapy continue?

The Menopause Society 2022 statement supports longer durations for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation [1]. The Premarin label says postmenopausal women should be re-evaluated periodically to determine whether treatment is still necessary [3].

›Will hot flashes come back after stopping?

SWAN found that frequent hot flashes or night sweats lasted a median of 7.4 years overall and 4.5 years after the final menstrual period [4]. That describes how long symptoms last, not what happens after stopping hormone therapy. Cognitive behavioral therapy, clinical hypnosis, SSRIs or SNRIs, gabapentin and fezolinetant have Level I support for vasomotor symptoms [2].

›What helps vaginal dryness?

Vaginal dryness becomes more common in postmenopause stage +2 in the STRAW+10 staging system [9]. For bothersome genitourinary symptoms not relieved by over-the-counter products, the Menopause Society recommends low-dose vaginal estrogen, vaginal DHEA (prasterone) or oral ospemifene [1].

References

1. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. The 2022 hormone therapy position statement of The North American Menopause Society
2. New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. The 2023 nonhormone therapy position statement of The North American Menopause Society
3. U.S. National Library of Medicine, DailyMed. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) prescribing information. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) label
4. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9. Duration of menopausal vasomotor symptoms over the menopause transition
5. U.S. Food and Drug Administration. U.S. Food and Drug Administration
6. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA
7. U.S. National Library of Medicine, DailyMed. Prempro / Premphase (conjugated estrogens and medroxyprogesterone acetate) prescribing information. Prempro / Premphase (conjugated estrogens and medroxyprogesterone acetate) label
8. U.S. National Library of Medicine, DailyMed. Veozah fezolinetant prescribing information. Veozah fezolinetant label
9. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging - PMC. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging - PMC